<DOC>
	<DOCNO>NCT01852604</DOCNO>
	<brief_summary>Parts A B study design evaluate safety , tolerability , efficacy pharmacokinetic profile samatasvir simeprevir administer combination ribavirin ( RBV ) 12 week treatment-naïve , Genotype ( GT ) 1b , 4 6 hepatitic C virus ( HCV ) -infected participant . Part C study design evaluate safety , tolerability , efficacy pharmacokinetic profile samatasvir , simeprevir , TMC647055 ritonavir ( RTV ) administer combination without RBV 12 week treatment-naïve interferon/RBV-treatment relapse , GT 1a 1b HCV-infected participant .</brief_summary>
	<brief_title>Samatasvir ( IDX719 ) Combinations With Simeprevir and/or TMC647055/Ritonavir With Without Ribavirin 12 Weeks Participants With Chronic Hepatitis C Infection ( MK-1894-005 )</brief_title>
	<detailed_description>Part A study randomize double-blind . Parts B C randomize open-label .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Must Genotype 1a , 1b , 4 6 HCV infection . Documented clinical history compatible chronic hepatitis C HCV treatmentnaïve interferon/RBVtreatment relapse ( Part C ) Must agree use acceptable double method birth control ( one must barrier method ) least 6 month last dose study drug . Female participant pregnant breastfeeding . Body Mass Index ( BMI ) &gt; 36 kg/m2 . Coinfected hepatitis B virus human immunodeficiency virus ( HIV ) . History hepatocellular carcinoma ( HCC ) finding suggestive possible HCC . History sign decompensated liver disease : ascites , variceal bleeding , hepatic encephalopathy , spontaneous bacterial peritonitis , clinical sign portal hypertension hepatic insufficiency . Has one know primary secondary cause liver disease , hepatitis C History , active , acute chronic , liver biliary injury due drug , toxin , nonHCV viral hepatitis , gallstone etiology Donated blood significant blood loss 30 day prior dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>chronic hepatitis C</keyword>
	<keyword>antiviral</keyword>
</DOC>